This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
B Certified

Newly B Certified Phastar names CEO and shifts ex-chief to COO

Posted by on 22 August 2023
Share this article

Biometrics-focused CRO Phastar has rejigged its executive team, appointing Graham Clark as its CEO and naming ex-chief Andrew MacGarvey as its chief operating officer (COO).

The Anglo-US contractor announced the changes last week, suggesting they will better position it for growth.

Phastar chairman Steve Kent said: “We are very pleased to welcome Graham to Phastar. Graham is known for building strong teams around a compelling vision, providing clear focus and results orientation, and managing teams through transformational change.

“We are confident that Graham is very well-placed to take Phastar to the next level as global specialist biometrics CRO and further enhance the value we deliver to our customers, employees, and life sciences industry as a whole.”

He added “The Board remains extremely appreciative of Andrew MacGarvey’s highly respected leadership over many years, which has built a strong organization and solidified Phastar’s market-leading position. We are delighted that we will continue to benefit from his experience in an operational role as COO moving forward.”

Before joining Phastar Clark was Managing Director with Phlexglobal, a global authority in Trial Master File (TMF) technology and services.

According to the firm, Clark adds strong operational and commercial experience to the executive team.

The appointment comes just a month after Phastar became a certified B Corporation by B Lab, meaning that it meets the highest standards of verified social and environmental performance, transparency, and legal accountability.

Certification comes after a stringent 12-month review to ensure protocols and procedures reflect the company’s commitment to high environment, social, and governance (EGS) standards.

At the time Andrew MacGarvey, Phastar CEO, said: “It is confirmation of our declaration to use our business as a ‘force for good’ by creating substantial value for our internal workforce, in addition to the wider community and society at large.

“One of our strategic objectives is to lead the CRO industry in corporate social responsibility, and being B Corp certified is a great first step to building on this commitment including signing up to the Net Zero pledge in the coming 12 months, in addition to conducting our first social impact assessment.”


Share this article

Sign up for Clinical Insider email updates